Feature | Cath Lab | September 12, 2017

Cardiovascular Research Foundation Appointed Juan Granada as New President, CEO

Distinguished cardiologist takes the helm of key interventional cardiology organization, sponsor of TCT

Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).


September 12, 2017 – The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). Granada was also appointed to CRF’s Board of Directors. A renowned leader in cardiology, he joined CRF in 2007 and served as executive director and chief innovation officer at the CRF Skirball Center for Innovation. He is also an assistant professor of medicine at Columbia University College of Physicians and Surgeons. 

Granada also has served as a member of the Editorial Board for Diagnostic and Interventional Cardiology (DAIC) magazine since 2010.

“Juan’s proven leadership skills, along with his expertise across preclinical, clinical, and educational initiatives will help CRF strengthen and expand its role in the development of innovative new technologies and therapies that will benefit people with heart disease worldwide,” said Eric B. Woldenberg, Esq., chairman of the CRF Board of Directors and a senior partner at Pryor Cashman LLP.

“Since its inception, CRF has played a major role in the rapid progress that has been made in interventional cardiology by establishing the safe use of new technologies and therapies for heart disease,” Granada said. “I am eager to take on this new role and work with my distinguished colleagues to ignite the next wave of innovation that will help doctors save and improve the quality of their patients’ lives.”

“CRF has grown due to a special blend of passion, creativity, and productivity, and Juan embodies our innovative culture,” said Martin B. Leon, M.D., founder and chairman emeritus of CRF and its co-director, medical research and education. “With his unique combination of advanced interventional skills, entrepreneurial spirit, and business insight, he has the visionary capacity to foresee new opportunities. Importantly, Juan is a caring and thoughtful people person who will catalyze communication and collaboration both inside and outside the organization.”

“Juan’s professionalism, creativity and ‘can do’ mindset make him an exceptional individual for this position,” added Gregg W. Stone, M.D., CRF’s co-director of medical research and education. “His knowledge of interventional cardiovascular medicine from bench to bedside coupled with extensive expertise in medical innovation will propel CRF to new levels of achievement in research and education.”

Granada is one of the world’s foremost investigators in the translational validation of novel cardiovascular therapies. He has helped develop and successfully validate several endovascular imaging and device technologies. He received his medical degree from the Institute of Health Sciences in Medellin, Colombia and finished his cardiovascular disease and interventional cardiology fellowships at Baylor College of Medicine in Houston, Texas.  

 

Video and Article Interviews With Dr. Juan Granada:

VIDEO: Bioresorbable Stent Failure Modes, Technique, Patient Selection and Future Development

VIDEO: Transcatheter Mitral Valve Technology, Anatomical Challenges

Advances and Future Directions for Transcatheter Valves

VIDEO: Transcatheter Mitral Valve Therapies in Development — TVT 2015

VIDEO: The Evolution of TAVR Technology — TVT 2015

Transcatheter Mitral Valve Replacement Devices in Development

Drug-eluting Balloons Enter the U.S. Market

Advances in Intravascular Imaging

 

For more information: www.crf.org


Related Content

News | Cath Lab

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is ...

Home March 26, 2026
Home
Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
Subscribe Now